181 related articles for article (PubMed ID: 21119195)
21. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Hall SM; Davie N; Klein N; Haworth SG
Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
[TBL] [Abstract][Full Text] [Related]
22. [Role of the Rho-kinase pathway in pulmonary arterial hypertension].
Fukumoto Y
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):178-81. PubMed ID: 24717605
[No Abstract] [Full Text] [Related]
23. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Maxey DM; Ivy DD; Ogawa MT; Feinstein JA
Pediatr Cardiol; 2013 Oct; 34(7):1628-36. PubMed ID: 23532466
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of targeted therapies for pulmonary hypertension in children.
Roldan T; Deiros L; Romero JA; Gutierrez-Larraya F; Herrero A; Del Cerro MJ
Pediatr Cardiol; 2014 Mar; 35(3):490-8. PubMed ID: 24141893
[TBL] [Abstract][Full Text] [Related]
25. [Drug combination treatment for pulmonary arterial hypertension].
Ghofrani HA; Hoeper MM
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S330-3. PubMed ID: 17139600
[TBL] [Abstract][Full Text] [Related]
26. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
27. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use.
Radicioni M; Bruni A; Camerini P
Eur J Pediatr; 2011 Aug; 170(8):1075-8. PubMed ID: 21380943
[TBL] [Abstract][Full Text] [Related]
29. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension.
Sugimura K; Fukumoto Y; Satoh K; Nochioka K; Miura Y; Aoki T; Tatebe S; Miyamichi-Yamamoto S; Shimokawa H
Circ J; 2012; 76(2):485-8. PubMed ID: 22185711
[TBL] [Abstract][Full Text] [Related]
30. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
31. Portopulmonary hypertension.
Nayak RP; Li D; Matuschak GM
Curr Gastroenterol Rep; 2009 Feb; 11(1):56-63. PubMed ID: 19166660
[TBL] [Abstract][Full Text] [Related]
32. [Pulmonary hypertension treatment: future prospects].
Baloira A
Arch Bronconeumol; 2007 Mar; 43(3):131-5. PubMed ID: 17386188
[No Abstract] [Full Text] [Related]
33. [Hopes and experiences in the treatment of severe pulmonary hypertension].
Monserrat L; Penas Lado M; Castro-Beiras A
Rev Esp Cardiol; 2003 Mar; 56(3):228-9. PubMed ID: 12622951
[No Abstract] [Full Text] [Related]
34. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
Pitsiou GG; Chavouzis N; Nakou C; Boutou AK; Argyropoulou P; Stanopoulos I
J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy and new types of agents for pulmonary arterial hypertension.
O'Callaghan DS; Gaine SP
Clin Chest Med; 2007 Mar; 28(1):169-85, ix. PubMed ID: 17338934
[TBL] [Abstract][Full Text] [Related]
36. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
[TBL] [Abstract][Full Text] [Related]
37. [Combination therapy in patients with pulmonary arterial hypertension].
Ewert R; Opitz CF; Schäper C; Gläser S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S187-90. PubMed ID: 18814093
[TBL] [Abstract][Full Text] [Related]
38. Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol.
Kataoka M; Satoh T; Manabe T; Anzai T; Yoshikawa T; Mitamura H; Ogawa S
Intern Med; 2004 Oct; 43(10):945-50. PubMed ID: 15575245
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
Hoeper MM; Faulenbach C; Golpon H; Winkler J; Welte T; Niedermeyer J
Eur Respir J; 2004 Dec; 24(6):1007-10. PubMed ID: 15572546
[TBL] [Abstract][Full Text] [Related]
40. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
